-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $81

Benzinga·08/07/2026 20:27:42
Listen to the news
RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $82 to $81.